CN103193770B - Replace benzothiazoles antifungal compound and preparation method thereof and application - Google Patents

Replace benzothiazoles antifungal compound and preparation method thereof and application Download PDF

Info

Publication number
CN103193770B
CN103193770B CN201310090710.3A CN201310090710A CN103193770B CN 103193770 B CN103193770 B CN 103193770B CN 201310090710 A CN201310090710 A CN 201310090710A CN 103193770 B CN103193770 B CN 103193770B
Authority
CN
China
Prior art keywords
acid
amino
cis
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310090710.3A
Other languages
Chinese (zh)
Other versions
CN103193770A (en
Inventor
盛春泉
朱杰
张万年
刘杨
张玲
缪震元
姚建忠
董国强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Second Military Medical University SMMU
Original Assignee
Second Military Medical University SMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Military Medical University SMMU filed Critical Second Military Medical University SMMU
Priority to CN201310090710.3A priority Critical patent/CN103193770B/en
Publication of CN103193770A publication Critical patent/CN103193770A/en
Application granted granted Critical
Publication of CN103193770B publication Critical patent/CN103193770B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention belongs to medical art.The invention provides a kind of replacement benzothiazole compound and pharmacy acceptable salt thereof, its general structure is as shown in formula I:

Description

Replace benzothiazoles antifungal compound and preparation method thereof and application
Technical field
The present invention relates to medical art, be specifically related to a kind of replacement benzothiazole compound newly---cis-N-{2-[(pentamethylene base carbonyl) amino] benzothiazol-6-yl }-3-[(replacements) amino] cyclohexyl Carbox amide and its esters and preparation method, and as the application of antifungal drug.
Background technology
In recent years, along with the widespread use of the treatment meanss such as antibiotic, tumor chemoradiotherapy and organ transplantation, and sharply the rising of acquired immune deficiency syndrome (AIDS) morbidity, the diseased colonies reading the deep fungal infections such as bacterium, aspergillus fumigatus and cryptococcus neoformans in vain increases considerably.Therefore, deep fungal infection has now become the lethal major cause of the major disease such as acquired immune deficiency syndrome (AIDS), tumour.But anti-deep fungal medicine desirable clinically still extremely lacks, various problem below existing medicine ubiquity.Azole drug (such as fluconazole) is a kind of antifungal drug of being used widely acting on lanosterol 14 α-demethylase (CYP51), but such medicine is owing to having restraining effect to human body cell cytochrome p 450 enzyme system, obvious drug-drug interactions can be caused, and antimicrobial spectrum is limited, invalid to Resistant strain.Polyene antibiotics (such as amphotericin B) is the first-selected medicine of a class acting on fungal cell's membrane lipid, but it makes application be subject to considerable restraint because toxic side effect is large.Fat peptide medicament (such as Caspofungin) is the class antifungal drug acting on fungal cell wall β-1,3 glucan synthase, but its complex structure, expensive, bioavailability is lower, and has hemolytic toxicity.Therefore, except carry out composition optimizes and preparation improvement for above-mentioned key agents except, searching antifungal drug research New Policy and novel target spot seem very urgent and necessary, to obtain the small-molecule drug with brand-new mechanism of action and brand new type.
N-mnyristoyl based transferase (NMT) whitely reads the growth such as bacterium and Cryptococcus neoformans and necessary enzyme of surviving, and being verified in recent years is the new target drone of antifungal drug effect.The some fungi NMT inhibitor of report demonstrates good anti-mycotic activity, is expected to develop into the novel antifungal drugs with brand-new mechanism of action.FTR1335 is the Inhibiting enzyme activity good benzothiazole class NMT inhibitor of report at present, and structural formula is as follows.But, FTR1335 antimicrobial spectrum is narrower, dialogue reads bacterium In-vitro Inhibitory Effect (K.Yamazaki, Y.Kaneko, K.Suwa, S.Ebara, K.Nakazawa, K.Yasuno, Synthesis ofpotent and selective inhibitors of Candida albicans N-myristoyltransferase based onthe benzothiazole structure, Bioorg Med Chem, 13 (2005) 2509-2522.), and there is no at present bibliographical information by structure of modification come spread F TR1335 antimicrobial spectrum and improve its anti-mycotic activity.
Summary of the invention
The object of the present invention is to provide a kind of replacement benzothiazole compound and its esters.Another object of the present invention is to provide described replacement benzothiazole compound and the preparation method of its esters.The third object of the present invention is to provide described replacement benzothiazole compound and its esters preparing the application in antifungal drug, topoisomerase enzyme inhibitor, antitumor drug, antiviral, antihypertensive drug or antithrombotic reagent.
Technical scheme of the present invention is: in order to spread F TR13335 antimicrobial spectrum and improve its anti-mycotic activity; the naphthalene nucleus part mainly concentrating on FTR13335 carries out structure of modification; obtain the cis-N-{2-of a class [(pentamethylene base carbonyl) is amino] benzothiazol-6-yl }-3-[(replacement) is amino] cyclohexyl Carbox amide, can as the inhibitor of fungi N-mnyristoyl based transferase (NMT).
A first aspect of the present invention, be to provide a kind of replacement benzothiazole compound, i.e. cis-N-{2-[(pentamethylene base carbonyl) is amino] benzothiazol-6-yl }-3-[(replacement) is amino] cyclohexyl Carbox amide, and pharmacy acceptable salt, its general structure is as shown in formula I:
In formula I, R represents replacement naphthalene nucleus or substituted aroma heterocycle,
A) the various substituting group positions replaced in naphthalene nucleus or substituted aroma heterocycle are other any positions being positioned at removing link position, can be monosubstituted, also can be polysubstituted, substituting group refers to: hydrogen, hydroxyl, methyl, ethyl, methoxyl group, oxyethyl group, nitro, cyano group, trifluoromethyl or halogen, and described halogen comprises F, Cl, Br, I;
B) substituted aroma heterocycle represents independently: quinoline, tetrahydroquinoline, isoquinoline 99.9, tetrahydroisoquinoline, pyridine, thiophene, thiazole, pyrazoles, furans, oxazole, isoxazole, pyridazine or pyrazine etc.
Formula I compound, R group preferably from:
(1) R group is the bromo-2-naphthalene of 1-;
(2) R group is 6-methoxyl group-2-naphthalene;
(3) R group is 1-naphthalene;
(4) R group is 2-methoxyl group-1-naphthalene;
(5) R group is 4-methoxyl group-1-naphthalene;
(6) R group is 2-oxyethyl group-1-naphthalene;
(7) R group is 2-quinoline;
(8) R group is 3-quinoline;
(9) R group is the chloro-3-quinoline of 2-;
(10) R group is 1,2,3,4-tetrahydroquinoline-3-base;
(11) R group is 4-quinoline;
(12) R group is 6-quinoline;
(13) R group is 1,2,3,4-tetrahydroquinoline-6-base;
(14) R group is 8-quinoline;
Part preferred compound is:
Cis-N-{2-[(cyclopentylcarbonyl) is amino] benzothiazol-6-yl }-3-[(3-quinolylmethyl) is amino] cyclohexyl methane amide (8),
Cis-N-{2-[(cyclopentylcarbonyl) is amino] benzothiazol-6-yl }-3-[(6-quinolylmethyl) is amino] cyclohexyl methane amide (12), or
Cis-N-{2-[(cyclopentylcarbonyl) is amino] benzothiazol-6-yl }-3-[(1,2,3,4-tetrahydroquinoline-6-base) methylamino-] cyclohexyl methane amide (13).
Above-mentioned benzothiazole compound conventionally can prepare the form of a pharmaceutical salts.Comprise its organic acid salt and inorganic acid salt: mineral acid includes, but is not limited to hydrochloric acid, sulfuric acid, phosphoric acid, bisphosphate, Hydrogen bromide, nitric acid etc., organic acid includes, but is not limited to acetic acid, toxilic acid, fumaric acid, tartrate, succsinic acid, lactic acid, tosic acid, Whitfield's ointment, oxalic acid etc.
A second aspect of the present invention, is to provide a kind of preparation method replacing benzothiazole compound and pharmacy acceptable salt thereof.
The building-up reactions flow process of the compounds of this invention is as follows:
Concrete steps are:
(A) N-(6-nitrobenzene thiazole-2-base) ring penta methane amide (II) is prepared
2-amino-6-nitrobenzothiazole (I) and cyclopentane-carboxylic acid are in methylene dichloride, through 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and DMAP condensation, stirring at room temperature reacts 16 hours, generates N-(6-nitrobenzene thiazole-2-base) ring penta methane amide (II);
(B) N-(6-aminobenzothiazole-2-base) ring penta methane amide (III) is prepared
Compound N-(6-nitrobenzene thiazole-2-base) ring penta methane amide (II) and tin protochloride are in ethanol, and heating reflux reaction 2 hours, obtains N-(6-aminobenzothiazole-2-base) ring penta methane amide (III);
(C) the cis-3-of the tertiary butyl-N-[(2-[(cyclopentylcarbonyl) is amino] benzothiazole-6-is amino) carbonyl] cyclohexylcarbamate (IV) is prepared
N-(6-aminobenzothiazole-2-base) ring penta methane amide (III) and cis-3-(tertiary fourth oxygen carboxylic is amino) hexahydrobenzoic acid are in methylene dichloride, add 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and I-hydroxybenzotriazole, stirring at room temperature reacts 18 hours, obtains the cis-3-of the tertiary butyl-N-[(2-[(cyclopentylcarbonyl) is amino] benzothiazole-6-is amino) carbonyl] cyclohexylcarbamate (IV);
(D) cis-3-amino-N-[2-(cyclopentylcarbonyl) is amino] benzothiazol-6-yl-cyclohexyl methane amide (V) is prepared
The cis-3-of the tertiary butyl-N-[(2-[(cyclopentylcarbonyl) is amino] benzothiazole-6-is amino) carbonyl] cyclohexylcarbamate (IV) is with methylene dichloride, add trifluoroacetic acid, stirring at room temperature reacts 1 hour, obtains cis-3-amino-N-[2-(cyclopentylcarbonyl) is amino] benzothiazol-6-yl-cyclohexyl methane amide (V);
(E) the cis-N-{2-of target compound [(cyclopentylcarbonyl) is amino] benzothiazol-6-yl is prepared }-3-[(replacement) is amino] cyclohexyl methane amide (VI)
The cis-3-amino of compound-N-[2-(cyclopentylcarbonyl) amino] benzothiazol-6-yl-cyclohexyl methane amide (V) and replacement naphthaldehyde or substd quinolines formaldehyde are in methyl alcohol, and mixed solution stirring at room temperature reacts 2 hours; Add sodium cyanoborohydride and 3-5 drips acetic acid, continue stirring reaction 10 hours, generate and prepare the cis-N-{2-of target compound [(cyclopentylcarbonyl) is amino] benzothiazol-6-yl-3-[(replacement) is amino] cyclohexyl methane amide (VI).
A third aspect of the present invention, is to provide described replacement benzothiazole compound and pharmacy acceptable salt is preparing the application in antifungal drug, topoisomerase enzyme inhibitor, antitumor drug, antiviral, antihypertensive drug or antithrombotic reagent.
Compound of the present invention is through antibacterial experiment in vitro, prove that majority of compounds has good anti-mycotic activity and wider antimicrobial spectrum, especially compound broad spectrum is greatly improved, and illustrates that this compounds can be used for preparing the medicine for the treatment of anti-fungal infection.
Compound of the present invention is that further investigation and exploitation new texture type antifungal drug open new approach.
Embodiment
Below in conjunction with specific embodiment, the invention will be further described.Should be understood that following examples only for illustration of the present invention but not for limiting scope of the present invention.
The preparation of embodiment 1:N-(6-nitrobenzene thiazole-2-base) ring penta methane amide (II)
Get 2-amino-6-nitrobenzothiazole (4.00g, 0.02mol, 1equiv) be dissolved in 50mL methylene dichloride with cyclopentane-carboxylic acid (2.28g, 0.02mol, 1equiv), add 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (5.75g, 0.03mol, 1.5equiv) and DMAP (0.40g, 2mmol, 0.1equiv), stirring at room temperature reaction 16h.After reaction terminates, reaction solution 5% salt pickling (3 × 30mL), 5% sodium bicarbonate is washed (3 × 30mL), and saturated nacl aqueous solution is washed (3 × 30mL), uses anhydrous Na 2sO 4dry. filter, evaporated under reduced pressure solvent, residue by silicagel column chromatography purification (developping agent: hexane:EtOAc=10:1, v/v), obtains faint yellow solid 5.66g, yield 97.3%. 1H-NMR(300MHz,CDCl 3):9.15(brs,1H),8.76(d,1H,J=2.4Hz),8.34(dd,1H,J=9.0,2.4Hz),7.82(d,1H,J=9.0Hz),2.80-2.96(m,1H),1.90-2.11(m,2H),1.54-1.90(m,6H).ESI-MS(m/z):290[M-1].
The preparation of embodiment 2:N-(6-aminobenzothiazole-2-base) ring penta methane amide (III)
Get compound ii (1.00g, 3.4mmol, 1equiv) and tin protochloride (2.30g, 10.2mmol, 3equiv) is dissolved in 50mL ethanol, heating reflux reaction 2h.After reaction terminates, evaporate to dryness reaction solution, adds 5% sodium hydroxide solution 50mL and 100mL ethyl acetate fully mixes vibration, and aqueous layer with ethyl acetate (2 × 100mL) extracts.Organic phase merges, and washes (3 × 30mL), anhydrous Na with saturated nacl aqueous solution 2sO 4dry.Filter, evaporated under reduced pressure solvent, residue with ethyl acetate 20mL recrystallization, obtains white solid 0.45g, yield 50.6%. 1H-NMR(300MHz,DMSO-d 6):11.97(s,1H),7.37(d,1H,J=8.5Hz),6.97(d,1H,J=1.5),6.68(dd,1H,J=8.5,1.5Hz),5.14(s,2H),2.83-2.97(m,1H),1.78-1.95(m,2H),1.45-1.95(m,6H).ESI-MS(m/z):262[M+1].
Embodiment 3: the preparation of the cis-3-of the tertiary butyl-N-[(2-[(cyclopentylcarbonyl) is amino] benzothiazole-6-is amino) carbonyl] cyclohexylcarbamate (IV)
Get III (1.00g, 3.83mmol, 1equiv) be dissolved in 25mL methylene dichloride with cis-3-(tertiary fourth oxygen carboxylic is amino) hexahydrobenzoic acid (0.93g, 3.83mmol, 1equiv), add 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (1.10g, 5.75mmol, 1.5equiv) and I-hydroxybenzotriazole (0.78g, 5.75mmol, 0.1equiv), stirring at room temperature reaction 18h.After reaction terminates, filter out white depositions, use 20mL washed with dichloromethane, obtain faint yellow solid 0.91g, yield 54.2%.1H-NMR(300MHz,DMSO-d6):12.45(s,1H),10.21(s,1H),8.50(d,1H,J=1.8Hz),7.83(d,1H,J=8.7Hz),7.68(dd,1H,J=8.7,1.8Hz),7.04(s,1H),3.07-3.22(m,1H),2.72-2.81(m,1H),2.55-2.66(m,1H),1.67-2.17(m,12H),1.57(s,9H),1.20-1.53(m,4H).ESI-MS(m/z):485[M-1].
Embodiment 4: the preparation of cis-3-amino-N-[2-(cyclopentylcarbonyl) is amino] benzothiazol-6-yl-cyclohexyl methane amide (V)
Get IV (0.35g, 0.72mmol, 1equiv) to be dissolved in 3mL methylene dichloride, add trifluoroacetic acid 3mL, stirring at room temperature reaction 1h, evaporated under reduced pressure solvent, adds 5% aqueous sodium carbonate 30mL and ethyl acetate 50mL, fully mixes vibration.Aqueous layer with ethyl acetate (2 × 20mL) extracts.Merge organic phase, wash (3 × 30mL) with saturated nacl aqueous solution, anhydrous Na 2sO 4dry.Filter, evaporated under reduced pressure solvent, obtains white solid 0.27g, yield 92.59%. 1H-NMR(300MHz,DMSO-d 6):10.08(s,1H),8.41(s,1H),7.73(d,1H,J=8.7Hz),7.62(d,1H,J=8.7Hz),4.58-5.52(brs,2H),2.99-3.16(m,1H),2.43-2.69(m,2H),1.60-2.16(m,12H),0.99-1.60(m,4H).ESI-MS(m/z):385[M-1].
Embodiment 5: cis-N-{2-[(cyclopentylcarbonyl) amino] benzothiazol-6-yl } preparation of-3-[(the bromo-2-menaphthyl of 1-) is amino] cyclohexyl methane amide (in table compound 1)
Getting compound is dissolved in methyl alcohol 10mL along the bromo-2-naphthaldehyde (0.091g, 0.39mmol, 1equiv) of V (0.15g, 0.39mmol, 1equiv) and 1-, mixed solution stirring at room temperature reaction 2h.Add sodium cyanoborohydride (0.025g, 0.39mmol, 1equiv) to reaction solution and 3-5 drips acetic acid, continue stirring reaction 10h.After reaction terminates, the direct silica gel mixed sample of reaction solution, combiflash companion purifying (developping agent: CH 2cl 2-MeOH=10:1, v/v), obtain faint yellow solid 0.081g, yield 33.9%.
Embodiment 6: cis-N-{2-[(cyclopentylcarbonyl) amino] benzothiazol-6-yl } preparation of-3-[(3-quinolylmethyl) is amino] cyclohexyl methane amide (in table compound 8)
Getting compound is dissolved in methyl alcohol 10mL along V (0.15g, 0.39mmol, 1equiv) and 3-quinoline aldehyde (0.061g, 0.39mmol, 1equiv), mixed solution stirring at room temperature reaction 2h.Add sodium cyanoborohydride (0.025g, 0.39mmol, 1equiv) to reaction solution and 3-5 drips acetic acid, continue stirring reaction 10h.After reaction terminates, the direct silica gel mixed sample of reaction solution, combiflash companion purifying (developping agent: CH 2cl 2-MeOH=10:1, v/v), obtain faint yellow solid 0.015g, yield 7.14%. 13C-NMR(75MHz,CD 3OD):177.51,175.78,159.40,152.23,148.37,146.62,138.70,136.00,133.85,131.65,129.97,129.28,129.28,129.07,128.68,121.64,120.42,113.54,57.33,47.74,46.10,45.30,34.05,31.34,31.34,31.21,30.07,27.05,27.05,24.67.ESI-MS(m/z):528[M+1].HR ESI-MS[M+1]:528.2443.
Embodiment 7: cis-N-{2-[(cyclopentylcarbonyl) amino] benzothiazol-6-yl } preparation of-3-[(6-quinolylmethyl) is amino] cyclohexyl methane amide (in table compound 12)
Getting compound is dissolved in methyl alcohol 10mL along V (0.15g, 0.39mmol, 1equiv) and 6-quinoline aldehyde (0.061g, 0.39mmol, 1equiv), mixed solution stirring at room temperature reaction 2h.Add sodium cyanoborohydride (0.025g, 0.39mmol, 1equiv) to reaction solution and 3-5 drips acetic acid, continue stirring reaction 10h.After reaction terminates, the direct silica gel mixed sample of reaction solution, combiflash companion purifying (developping agent: CH 2cl 2-MeOH=10:1, v/v), obtain faint yellow solid 0.022g, yield 10.59%. 13C-NMR(75MHz,CD 3OD):177.49,176.36,159.42,151.17,148.18,146.52,138.86,138.27,136.17,133.82,131.99,129.81,129.32,128.53,122.78,121.62,120.46,113.53,56.57,50.58,46.10,45.82,35.85,31.34,31.34,30.73,30.20,27.05,27.05,25.14.ESI-MS(m/z):528[M+1].HR ESI-MS[M+1]:528.2443.
Embodiment 8: cis-N-{2-[(cyclopentylcarbonyl) amino] benzothiazol-6-yl } preparation of-3-[(1,2,3,4-tetrahydroquinoline-6-base) methylamino-] cyclohexyl methane amide (in table compound 13)
Getting compound is dissolved in methyl alcohol 10mL along V (0.15g, 0.39mmol, 1equiv) and 6-quinoline aldehyde (0.061g, 0.39mmol, 1equiv), mixed solution stirring at room temperature reaction 2h.Add sodium cyanoborohydride (0.025g, 0.39mmol, 1equiv) to reaction solution and 3-5 drips acetic acid, continue stirring reaction 10h.After reaction terminates, the direct silica gel mixed sample of reaction solution, combiflash companion purifying (developping agent: CH 2cl 2-MeOH=10:1, v/v), obtain faint yellow solid 0.014g, yield 8.11%.Compound 13 prepares the by product obtained in compound 12 process.
In embodiment, agents useful for same is commercially available analytical pure.
In table 1, other compounds are with different replacement naphthalene nucleus or quinoline ring for synthesis material, as listed in table 1, repeat the step in embodiment 5, just can synthesize required replacement benzothiazole compound.
The chemical structure of table 1 preferred compound and 1h-NMR and MS data
Embodiment 9: cis-N-{2-[(pentamethylene base carbonyl) amino] benzothiazol-6-yl of the present invention's synthesis } antifungic action of-3-[(replacements) amino] cyclohexyl Carbox amide
(1) experimental technique: adopt conventional antibacterial experiment in vitro method (referring to: Antimicrob AgentsChemother1995,39 (5): 1169)
1. materials and methods
(1) experimental strain
This experiment has selected following 6 kinds of important human body cause illness's standard fungal bacterial strains as screening object, and fungal bacterial strain provides by Changhai hospital of The 2nd Army Medical College Mycology Lab (or purchased from institute of materia medica of the Chinese Academy of Sciences).
1) Candida albicans (Candida albicans, type strain SC5314);
2) Candida parapsilosis (Candida parapsilosis, clinical strain 0306392);
3) Candida glabrata (Candida glabrata, type strain 537)
4) Cryptococcus neoformans (Cryptococcus neoformans, type strain BLS108);
5) trichophyton (Trichophyton rubrum, clinical strain 0501124);
6) gypsum shape sporidiole bacteria (Microsporum gypseum, clinical strain Cmccfmza).
(2) test method
Bacteria suspension is prepared: a. Cryptococcus neoformans and candidiasis are cultivated 16 hours through YEPD liquid nutrient medium 35 DEG C, twice activation, with blood cell counting plate counting, with RPM1640 liquid nutrient medium adjustment concentration to 1 × 10 3~ 5 × 10 3individual/mL.B. thread fungus (trichophyton) cultivates (35 DEG C) one week and (28 DEG C) two weeks respectively through SDA inclined-plane, and twice activation, adds RPM1640 liquid nutrient medium and blow and beat with suction pipe, spore is made to be free in RPM1640 liquid, through four layers of filtered through gauze, counting, adjustment concentration to 1 × 10 3~ 5 × 10 3individual/mL.
Drug solution preparing: get testing compound of the present invention and be dissolved in methyl-sulphoxide, is made into the medicament storage liquid of 3.2mg/mL, tests front RPM1640 and is diluted to 320 μ g/mL.
Inoculation: 96 No. 1, orifice plate holes add RPM1640200 μ l and make blank, 3-12 hole respectively adds bacteria suspension 100 μ l, No. 2 holes add bacteria suspension 180 μ l and liquid 20 μ l, the drug level in 2-11 hole makes 9 grade of 2 doubling dilution, and each hole drug level is respectively 32,16,8,4,2,1,0.5,0.25,0.125 μ g/mL.No. 12 holes do not add liquid, make positive control.
Cultivate and detect: set Positive control wells optical density value (OD value) as 100%, with optical density value than Positive control wells lower than 80% lowest concentration of drug for minimal inhibitory concentration value (MIC).
(2) experimental result
Antibacterial experiment in vitro the results are shown in Table 2.
The antimycotic minimal inhibitory concentration value of table 2 part selected objective target Compound ira vitro (MIC 80, μ g/mL)
Above-mentioned experimental result shows, compared with positive control drug, in compound of the present invention, major part has good anti-mycotic activity and wider antimicrobial spectrum, and especially compound broad spectrum is greatly improved, and illustrates that this compounds can be used for preparing the medicine for the treatment of anti-fungal infection.
More than show and describe ultimate principle of the present invention, principal character and advantage of the present invention.The technician of the industry should understand; the present invention is not restricted to the described embodiments; what describe in above-described embodiment and specification sheets just illustrates principle of the present invention; the present invention also has various changes and modifications without departing from the spirit and scope of the present invention, and these changes and improvements all fall in the claimed scope of the invention.Application claims protection domain is defined by appending claims and equivalent thereof.

Claims (4)

1. replace benzothiazole compound and a pharmacy acceptable salt thereof, described benzothiazole compound is:
Cis-N-{2-[(cyclopentylcarbonyl) is amino] benzothiazol-6-yl }-3-[(3-quinolylmethyl) is amino] cyclohexyl methane amide,
Cis-N-{2-[(cyclopentylcarbonyl) is amino] benzothiazol-6-yl }-3-[(6-quinolylmethyl) is amino] cyclohexyl methane amide, or
Cis-N-{2-[(cyclopentylcarbonyl) is amino] benzothiazol-6-yl }-3-[(1,2,3,4-tetrahydroquinoline-6-base) methylamino-] cyclohexyl methane amide.
2. one according to claim 1 replaces benzothiazole compound and pharmacy acceptable salt thereof, and it is characterized in that, described pharmacy acceptable salt is organic acid salt or inorganic acid salt.
3. one according to claim 2 replaces benzothiazole compound and pharmacy acceptable salt thereof, and it is characterized in that, described mineral acid is hydrochloric acid, sulfuric acid, phosphoric acid, bisphosphate, Hydrogen bromide, or nitric acid; Organic acid is acetic acid, toxilic acid, fumaric acid, tartrate, succsinic acid, lactic acid, tosic acid, Whitfield's ointment, or oxalic acid.
4. a replacement benzothiazole compound as claimed in claim 1 and pharmacy acceptable salt thereof are preparing the application in antifungal drug.
CN201310090710.3A 2013-03-20 2013-03-20 Replace benzothiazoles antifungal compound and preparation method thereof and application Expired - Fee Related CN103193770B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310090710.3A CN103193770B (en) 2013-03-20 2013-03-20 Replace benzothiazoles antifungal compound and preparation method thereof and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310090710.3A CN103193770B (en) 2013-03-20 2013-03-20 Replace benzothiazoles antifungal compound and preparation method thereof and application

Publications (2)

Publication Number Publication Date
CN103193770A CN103193770A (en) 2013-07-10
CN103193770B true CN103193770B (en) 2015-10-28

Family

ID=48716606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310090710.3A Expired - Fee Related CN103193770B (en) 2013-03-20 2013-03-20 Replace benzothiazoles antifungal compound and preparation method thereof and application

Country Status (1)

Country Link
CN (1) CN103193770B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015255714B2 (en) * 2014-05-09 2019-12-12 Kineta, Inc. Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
CN107158385B (en) * 2016-03-14 2020-07-14 苏州大学 Application of RIP3 inhibitor in preparation of anti-platelet thrombosis drugs
CN111763201A (en) * 2020-03-03 2020-10-13 中国药科大学 Benzothiazole compound and medical application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320124A (en) * 1998-07-30 2001-10-31 曾尼卡有限公司 Benzazoles: benzoxazole, benzthiazole and benzimidazole derivatives
CN1789253A (en) * 2005-12-28 2006-06-21 华中师范大学 Benzothiazole derivatives synthesis and sterilization property thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006070014A (en) * 2004-08-04 2006-03-16 Hisamitsu Medical Kk 2-aminobenzothiazole derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320124A (en) * 1998-07-30 2001-10-31 曾尼卡有限公司 Benzazoles: benzoxazole, benzthiazole and benzimidazole derivatives
CN1789253A (en) * 2005-12-28 2006-06-21 华中师范大学 Benzothiazole derivatives synthesis and sterilization property thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"3D-QSAR and molecular docking studies on benzothiazole derivatives as Candida albicans N-myristoyltransferase inhibitors";Chunquan Sheng，等;《European Journal of Medicinal Chemistry》;20061118;第42卷(第4期);第477-486页 *
"N-肉豆蔻酰基转移酶——抗真菌药物作用新靶点";朱杰，等;《药学学报》;20051231;第40卷(第9期);第775-781页 *
"Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure";Kazuo Yamazaki，等;《Bioorganic & Medicinal Chemistry》;20050401;第13卷(第7期);第2509–2522页 *

Also Published As

Publication number Publication date
CN103193770A (en) 2013-07-10

Similar Documents

Publication Publication Date Title
CN104718213B (en) 5,5 heteroaromatic anti-infective compounds
WO2004098494A2 (en) Compounds, compositions, and methods
US7915276B2 (en) Berberrubine derivatives having antifungal activities
CN103193770B (en) Replace benzothiazoles antifungal compound and preparation method thereof and application
JP5404607B2 (en) Aniline derivative having anti-RNA virus action
CN110551072A (en) quinoxaline-N 1, N 4 -dioxide derivative with DNA topoisomerase activity inhibition function, preparation method and application
CN107325093A (en) Have the thiourea synthesis of antibacterial activity and apply
CN111057035B (en) Baicalein derivative and preparation method and application thereof
CN101077866B (en) Substituted benzoxazoles antifungal compounds and preparation method thereof
CN103254191B (en) Substituted aroma four lopps antifungal compound and preparation method thereof and application
CN109485607B (en) Beta-azole-phenyl ketone derivative and application thereof
KR101620377B1 (en) Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents
KR20120097407A (en) New secondary 8-hydroxyquinoline-7-carboxamide derivatives
CN102212030B (en) Substituted tetrahydrocarbazole antifungal compounds and preparation method thereof
CN106699726B (en) A kind of thiochromanone derivative and its preparation method and application
CN111533693A (en) Cinnamic acid amide diazole derivative and application thereof in antifungal drugs
CN109400573B (en) Benzo [ d ] [1,3] dioxole compound, preparation method and application thereof
CN104961707B (en) Substituted thiazole ketone secretory protease inhibitors and preparation method thereof
CN109608447A (en) Benzothiazole diazole analog derivative and its preparation method and application
CN112645926B (en) Sertraline derivative and preparation method and application thereof
CN110734412B (en) Benzothiazole derivative, synthesis method thereof and application of benzothiazole derivative as antibacterial drug
CN109020886B (en) Alkyl amino quinoline compound and preparation method and application thereof
CN107501255B (en) A kind of Chinese mugwort Saperconazole derivative and application thereof
CN103265525A (en) Substituted thieno-quinone compounds, and preparation method and application thereof
CN109438471B (en) Tricyclic isoxazole compound and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Sheng Chunquan

Inventor after: Zhu Jie

Inventor after: Zhang Wannian

Inventor after: Liu Yang

Inventor after: Zhang Ling

Inventor after: Jiu Zhenyuan

Inventor after: Yao Jianzhong

Inventor after: Dong Guoqiang

Inventor before: Sheng Chunquan

Inventor before: Zhang Wannian

Inventor before: Liu Yang

Inventor before: Zhang Ling

Inventor before: Jiu Zhenyuan

Inventor before: Yao Jianzhong

Inventor before: Dong Guoqiang

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: SHENG CHUNQUAN ZHANG WANNIAN LIU YANG ZHANG LING MIAO ZHENYUAN YAO JIANZHONG DONG GUOQIANG TO: SHENG CHUNQUAN ZHU JIE ZHANG WANNIAN LIU YANG ZHANG LING MIAO ZHENYUAN YAO JIANZHONG DONG GUOQIANG

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151028

Termination date: 20160320

CF01 Termination of patent right due to non-payment of annual fee